JP2016088937A - エボラウイルスに対する抗体および抗体の製造方法 - Google Patents
エボラウイルスに対する抗体および抗体の製造方法 Download PDFInfo
- Publication number
- JP2016088937A JP2016088937A JP2015214827A JP2015214827A JP2016088937A JP 2016088937 A JP2016088937 A JP 2016088937A JP 2015214827 A JP2015214827 A JP 2015214827A JP 2015214827 A JP2015214827 A JP 2015214827A JP 2016088937 A JP2016088937 A JP 2016088937A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ebola virus
- ebola
- antibodies
- ostrich
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001115402 Ebolavirus Species 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 25
- 230000003053 immunization Effects 0.000 claims abstract description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 13
- 208000015181 infectious disease Diseases 0.000 claims abstract description 12
- 235000013601 eggs Nutrition 0.000 claims abstract description 8
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 64
- 241000272534 Struthio camelus Species 0.000 claims description 55
- 102000002322 Egg Proteins Human genes 0.000 claims description 21
- 108010000912 Egg Proteins Proteins 0.000 claims description 21
- 235000013345 egg yolk Nutrition 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 10
- 239000000645 desinfectant Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000271566 Aves Species 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 18
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 28
- 241000287828 Gallus gallus Species 0.000 description 21
- 235000013330 chicken meat Nutrition 0.000 description 21
- 241000286209 Phasianidae Species 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 241000271567 Struthioniformes Species 0.000 description 10
- 239000007921 spray Substances 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 235000003385 Diospyros ebenum Nutrition 0.000 description 3
- 241000792913 Ebenaceae Species 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 239000005708 Sodium hypochlorite Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241001115394 Reston ebolavirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001115376 Sudan ebolavirus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241001115400 Zaire ebolavirus Species 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229940034794 benzylparaben Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- -1 preventive mask Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Textile Engineering (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
Abstract
【解決手段】本発明は、エボラウイルスのリコンビナント蛋白質を抗原として雌性鳥類に免疫する工程と、前記雌性鳥類が産卵した卵の卵黄から抗体を得る工程を含むことを特徴とするエボラウイルス抗体の製造方法を提供する。本発明に係る方法は、リコンビナント蛋白質を用いるため、感染の心配がない。したがって、通常の飼育場所で抗体を産生することができ、さらに、作製された抗体はエボラウイルスを無力化することが期待できる。
【選択図】図1
Description
<抗原>
抗原は、バキュロウイルスベクターにEbola virus(subtype Sudan,strain Gulu)のGlyprotein遺伝子(Met−Asp637)を組み込み、カイコ細胞で作製したリコンビナント蛋白質を用いた。このリコンビナント蛋白質を以後「スーダンエボラ蛋白質」と呼ぶ。
成熟したメス鳥(ダチョウ、ニワトリ、ウズラ)を用いた。スーダンエボラ蛋白質液(蛋白量100μg)をフロイントの完全アジュバント0.2mLと混和し、5羽のダチョウそれぞれに初回免疫した。また、この抗原を個別に5羽のニワトリ、5羽のウズラにも接種した。つまり、ダチョウもニワトリもウズラも同量の抗原(スーダンエボラ蛋白質)を接種したことになる。初回免疫後、2週目と4週目に50μgの抗原とフロイントの不完全アジュバントの混和液を、各鳥に追加免疫した。
各卵黄から得られた抗体のスーダンエボラ蛋白質に対する反応性はELISAにより検証した。具体的には、まず96穴ELISAプレートの各穴にスーダンエボラ蛋白質をそれぞれ10μgを別々に固層化した(室温で4時間)。
<抗原>
抗原は、バキュロウイルスベクターにEbola virus (Subtype Zaire)のGlyprotein遺伝子(膜貫通領域欠く全長)を組み込み、カイコ細胞で作製したリコンビナント蛋白質を用いた。このリコンビナント蛋白質を以後「ザイールエボラ蛋白質」と呼ぶ。
成熟したメス鳥(ダチョウ、ニワトリ、ウズラ)を用いた。ザイールエボラ蛋白質液(蛋白量100μg)をフロイントの完全アジュバント0.2mLと混和し、5羽のダチョウそれぞれに初回免疫した。この抗原を、5羽のニワトリ、5羽のウズラにも接種した。ダチョウもニワトリもウズラも同量の抗原を接種したことになる。
得られた卵黄抗体のザイールエボラ蛋白質に対する反応性をELISAにより検証した。96穴ELISAプレートの各穴にザイールエボラ蛋白質をそれぞれ10μgを別々に固層化した(室温で4時間)。その後、抗ザイールエボラダチョウ抗体(各5羽のダチョウから得た卵黄からの抗体の混合物)、抗ザイールエボラニワトリ抗体(各5羽のニワトリから得た卵黄からの抗体の混合物)、抗ザイールエボラウズラ抗体(各5羽のウズラから得た卵黄からの抗体の混合物)の段階希釈液(原液は2mg/mL)を各穴に滴下し、室温で1時間反応させ、洗浄後、各抗体に対するHRP標識2次抗体を室温で1時間反応させた。
次に抗スーダンエボラダチョウ抗体と、抗ザイールエボラダチョウ抗体の各抗原に対する結合性をサンドイッチELISA法により確認した。一次抗体は、スーダンエボラ蛋白質およびザイールエボラ蛋白質をマウスに免疫することで得られた抗体を用いた。それぞれ抗スーダンエボラマウス抗体、抗ザイールエボラマウス抗体と呼ぶ。
実施例1で作製した抗スーダンエボラダチョウ抗体と、実施例2で作製した抗ザイールエボラダチョウ抗体を用いて、以下のような消毒剤を作製した。なお、「ダチョウ抗体」は、抗スーダンエボラダチョウ抗体若しくは抗ザイールエボラダチョウ抗体のいずれかを表す。
ダチョウ抗体溶液 0.5質量%
水 95質量%
パラペン 0.5質量%
スクロース 4質量%
なお、ダチョウ抗体溶液は15mg/mLのタンパク濃度の液体である。ダチョウ抗体は0.075質量%に相当する。
実施例4と同様に以下の組成の消毒剤を作製した。なお、「ダチョウ抗体」は、抗スーダンエボラダチョウ抗体若しくは抗ザイールエボラダチョウ抗体のいずれかを表す。
ダチョウ抗体溶液 0.5質量%
アルコール 65質量%
水 30質量%
パラペン 0.5質量%
スクロース 4質量%
なお、ダチョウ抗体溶液は15mg/mLのタンパク濃度の液体である。ダチョウ抗体は0.075質量%に相当する。
Claims (9)
- エボラウイルスのリコンビナント蛋白質を抗原として雌性鳥類に免疫する工程と、
前記雌性鳥類が産卵した卵の卵黄から抗体を得る工程を含むことを特徴とする抗エボラウイルス抗体の製造方法。 - 前記雌性鳥類がダチョウであることを特徴とする請求項1に記載された抗エボラウイルス抗体の製造方法。
- ダチョウの黄卵抗体であって、エボラウイルスのグリプロテイン遺伝子から作製したリコンビナント蛋白質に結合する抗体。
- 請求項3の抗体と、防腐剤と、安定剤と、水からなるエボラウイルス用消毒剤。
- 請求項3の抗体を有するマスク。
- 請求項3の抗体を有するエアコンフィルタ。
- 請求項3の抗体を表面に担持された感染予防服。
- 請求項3の抗体を用いた検査キット。
- 請求項3の抗体と生理食塩水を含むエボラウイルス用治療剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014223551 | 2014-10-31 | ||
JP2014223551 | 2014-10-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020109104A Division JP2020172497A (ja) | 2014-10-31 | 2020-06-24 | エボラウイルス用治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016088937A true JP2016088937A (ja) | 2016-05-23 |
Family
ID=55857000
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015214827A Pending JP2016088937A (ja) | 2014-10-31 | 2015-10-30 | エボラウイルスに対する抗体および抗体の製造方法 |
JP2020109104A Pending JP2020172497A (ja) | 2014-10-31 | 2020-06-24 | エボラウイルス用治療剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020109104A Pending JP2020172497A (ja) | 2014-10-31 | 2020-06-24 | エボラウイルス用治療剤 |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP2016088937A (ja) |
WO (1) | WO2016067637A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019087372A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202000030125A1 (it) * | 2020-12-09 | 2022-06-09 | Grafica Veneta S P A | Mascherina perfezionata. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630144B1 (en) * | 1999-08-30 | 2003-10-07 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies to Ebola glycoprotein |
WO2007026689A1 (ja) * | 2005-08-29 | 2007-03-08 | Japan Science And Technology Agency | ダチョウを用いた抗体、及びその作製方法 |
JP2009023985A (ja) * | 2007-01-11 | 2009-02-05 | Osaka Prefecture Univ | インフルエンザウイルスに対する抗体の産生方法 |
JP2010013361A (ja) * | 2008-07-01 | 2010-01-21 | Ostrich Pharma Kk | ノロウイルスに対する抗体及び抗体の作成方法 |
WO2012050193A1 (ja) * | 2010-10-14 | 2012-04-19 | 学校法人 埼玉医科大学 | エボラウイルスリポソームワクチン |
US20120164153A1 (en) * | 2009-09-02 | 2012-06-28 | The Government Of The United States, As Represented By The Secretary Of The Army | Monoclonal antibodies against glycoprotein of ebola sudan boniface virus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2002078738A1 (ja) * | 2001-03-26 | 2004-10-07 | 鈴木 宏治 | 血液レオロジー改善剤 |
-
2015
- 2015-10-30 WO PCT/JP2015/005489 patent/WO2016067637A1/ja active Application Filing
- 2015-10-30 JP JP2015214827A patent/JP2016088937A/ja active Pending
-
2020
- 2020-06-24 JP JP2020109104A patent/JP2020172497A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630144B1 (en) * | 1999-08-30 | 2003-10-07 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies to Ebola glycoprotein |
WO2007026689A1 (ja) * | 2005-08-29 | 2007-03-08 | Japan Science And Technology Agency | ダチョウを用いた抗体、及びその作製方法 |
JP2009023985A (ja) * | 2007-01-11 | 2009-02-05 | Osaka Prefecture Univ | インフルエンザウイルスに対する抗体の産生方法 |
JP2010013361A (ja) * | 2008-07-01 | 2010-01-21 | Ostrich Pharma Kk | ノロウイルスに対する抗体及び抗体の作成方法 |
US20120164153A1 (en) * | 2009-09-02 | 2012-06-28 | The Government Of The United States, As Represented By The Secretary Of The Army | Monoclonal antibodies against glycoprotein of ebola sudan boniface virus |
WO2012050193A1 (ja) * | 2010-10-14 | 2012-04-19 | 学校法人 埼玉医科大学 | エボラウイルスリポソームワクチン |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019087372A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
WO2019088230A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
Also Published As
Publication number | Publication date |
---|---|
JP2020172497A (ja) | 2020-10-22 |
WO2016067637A1 (ja) | 2016-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106715474B (zh) | 稳定化的流感血凝素茎区三聚体及其用途 | |
CN1958608B (zh) | 抗禽流感特异性IgY的制备方法及其制剂 | |
Wallach et al. | Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice | |
JPH05506233A (ja) | 赤血球の表面に結合した抗原を含むワクチン | |
JP6955324B2 (ja) | 医薬化合物を評価するための新規動物モデル | |
JP2020172497A (ja) | エボラウイルス用治療剤 | |
Ellis et al. | Phage‐display library biopanning as a novel approach to identifying nematode vaccine antigens | |
CN112094341A (zh) | 抗新型冠状病毒的IgY中和抗体及其制备方法、制剂和应用 | |
Adams et al. | Cross-immunity between Haemonchus contortus and Trichostrongylus colubriformis in sheep | |
Bimler et al. | Matrix protein 2 extracellular domain-specific monoclonal antibodies are an effective and potentially universal treatment for influenza A | |
US20110166328A1 (en) | Avian Antibodies Specific to Influenza Virus and Technologically Simple Methods of Their Manufacture and Use | |
Li et al. | Egg yolk IgY against RHDV capsid protein VP60 promotes rabbit defense against RHDV infection | |
JP2017006008A (ja) | Mers用抗体および抗血清 | |
WO2017037126A1 (en) | Novel proteins and detection methods | |
Tsukamoto et al. | Protection against infectious bronchitis virus, a corona virus infection, using ostrich antibodies | |
Lila et al. | Enhanced immune sera and vaccine: safe approach to treat scorpion envenoming | |
Findlay-Wilson et al. | Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins | |
Kadiyala et al. | Preparation of ingestible antibodies to neutralize the binding of SarsCoV2 RBD (receptor binding domain) to human ACE2 Receptor | |
Molina et al. | Immune response in goats vaccinated with thiol‐binding proteins from Haemonchus contortus | |
US11787845B1 (en) | Synthetic plasmodium antigens, compositions, and uses thereof | |
Mazza et al. | Antibody isotype responses to the Schistosoma mansoni schistosomulum in the CBA/N mouse induced by different stages of the parasite life cycle | |
Sudjarwo et al. | Purification and characterization protein of anti-dengue specific immunoglobulin Y for diagnostic kit of dengue | |
JP3078013B2 (ja) | ワクチン接合体の使用方法、ワクチン調整物および製造品 | |
Dinga et al. | Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB 05‐09 antigen could be a malaria vaccine candidate | |
CN103948622B (zh) | 羧甲基葡聚糖在制备提高禽流感疫苗抗体阳性率药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20151117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191001 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191202 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200624 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200624 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200701 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200707 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20200731 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20200804 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210323 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210420 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210608 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210713 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210713 |